Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR, Waldvogel FA, Perl TM, Jacobs MR, Moellering RC

Idioma: Español
Referencias bibliográficas: 148
Paginas: 236-261
Archivo PDF: 156.10 Kb.

FRAGMENTO

Antecedentes: desde la emergencia de Staphylococcus aureus resistente a meticilina, el glucopéptido vancomicina ha sido el único tratamiento uniformemente efectivo para las infecciones estafilocócicas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.

2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. Villanova, Pa.: National Committee for Clinical Laboratory Standards, 1997.

3. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.

4. Geraci JE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Antibiotic annual 1955-1956. New York: Medical Encyclopedia, 1956:90-106.

5. Ziegler DW. Vancomycin, a new antibiotic. II. In vitro antibacterial studies. In: Antibiotic annual 1955-1956. New York: Medical Encyclopedia, 1956:612-8.

6. Chuard C, Vaudaux P, Waldvogel FA, Lew DP. Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics. Antimicrob Agents Chemother 1993;37:625-32.

7. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.

8. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998;104:7S-10S.

9. Moreira B, Boyle-Vavra S, deJonge BL, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1788-93.

10. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329-34.

11. Nosocomial Enterococci resistant to vancomycin United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42:597-9.

12. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.

13. Murray BE. Vancomycin-resistant Enterococci. Am J Med 1997;102:284-93.

14. Noskin GA. Vancomycin-resistant Enterococci: Clinical, microbiologic, and epidemiologic features. J Lab Clin Med 1997;130:14-20.

15. Palmer SM, Rybak MJ. Vancomycin-resistant Enterococci. Pharmacotherapy 1996;16:819-29.

16. Fraimow HS, Jungkind DL, Lander DW, et al. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann Intern Med 1994;121:22-26.

17. Fitzpatrick B, Harrington S, Smith D, et al. An outbreak of vancomycin dependent Enterococci in an oncology center. Presented at 35th Annual Infectious Diseases Society of America Annual Meeting, September 13-16, 1997, San Francisco, CA.

18. Perl TM, DeLisle S. The emergence and control of vancomycinresistant Enterococci. Scientific Exchange, 1998.

19. Loudon K, Burnie JP. Is it time to stop searching for MRSA? Constant vigilance is needed to halt the emergence of resistance to vancomycin. BMJ 1997;315:59.

20. Veach LA, Pfaller MA, Barret M, Koontz FP, Wenzel RP. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990;28:2064-8.

21. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.

22. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6.

23. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.

24. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.

25. Sierarzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.

26. Interim guidelines for prevention and control staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8.

27. Witte W. Medical consequences of antibiotic use in agriculture. Science 1998;279:996-7.

28. Ross TW. Infectious disease challenge: Vancomycin-resistant Enterococcus and Staphylococcus. Drug Topics 1998;142:76- 83.

29. Bonafede M, Rice LB. Emerging antibiotic resistance. J Lab Clin Med 1997;130:558-66.

30. Murray BE. Diversity among multidrog-resistant Enterococci. Emerg Infect Dis 1998;4:37-47.

31. Coque TM, Tomayko JF, Ricke SC, et al. Vancomycin-resistant Enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605-9.

32. Woodford N, Chadwick PR, Morrison D, Cookson BD. Strains of glycopeptide-resistant Enterococcus faecium can alter their van genotypes during an outbreak. J Clin Microbiol 1997;35:2966-8.

33. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.

34. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol lnfect Dis 1997;29:95-102.

35. Bonilla HF, Zervos MA, Lyons MJ, et al. Colonization with vancomycin-resistant Enterococcus faecium: Comparison of a long-term care unit with an acute-care hospital. Infect Control Hosp Epidemiol 1997;18:333-9.

36. Henning KJ, Delencastre H, Eagan J, et al. Vancomycinresistant Enterococcus faecium on a pediatric oncology ward: Duration of stool shedding and incidence of clinical infection. Pediatr lnfect Dis J 1996:15:848-54.

37. Nourse C, Murphy H, Byrne C, et al. Control of a nosocomial outbreak of vancomycin-resistant Enterococcus faecium in a paediatric oncology unit: Risk factors for colonization. Eur J Pediatr 1998;157:20-27.

38. Shekar R, Chico G, Bass SN, et al. Household transmission of vancomycin-resistant Enterococcus faecium. Clin lnfect Dis 1995;21:1511.

39. Weber Di, Rutala WA. Role of environmental contamination in the transmission of vancomycin-resistant Enterococci. infect Control Hosp Epidemiol 1997;18:306-9.

40. Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant Enterococci on fingertips and environmental surfaces. lnfect Control Hosp Epidemiol 1995;16:577- 81.

41. Bonilla HF, Zervos MJ, Kauffman CA. Long term survival of vancomycin-resistant Enterococcus faecium on a contaminated surface. lnfect Control Hosp Epidemiol 1996;17:770-2.

42. Porwancher R, Sheth A, Remphrey S, et al. Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: Possible transmission by an electronic ear-probe thermometer. lnfect Control Hosp Epidemiol 1997;18:771-2.

43. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonization of patients and environment with vancomycinresistant Enterococci. Lancet 1996;348:1615-9.

44. Kirk M, Hill RLR, Casewell MW, Beighton D. Isolation of vancomycin-resistant Enterococci from supermarket poultry. Adv Exp Med Biol 1997;418:289-91.

45. Van den Bogaard AE, Jensen LB, Stobberingh EE. Vancomycin-resistant Enterococci in turkeys and farmers. N Engl J Med 1997;337:1558-9.

46. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 1994;34:507-14.

47. Bates J. Epidemiology of vancomycin-resistant Enterococci in the community and the relevance of farm animals to human infection. J Hosp Infect 1997;37:89-101.

48. Das I, Fraise A, Wise R. Are glycopeptide-resistant Enterococci in animals a threat to human beings? Lancet 1997;349:997- 8.

49. La¡ KK, Fontecchio SA, Kelley AL. The epidemiology of fecal carriage of vancomycin-resistant Enterococci. lnfect Control Hosp Epidemiol 1997;18:762-5.

50. Roghmann MC, Qaiyumi A, Schwalbe R, Morris JG. Natural history of colonization with vancomycin-resistant Enterococcus faecium. lnfect Control Hosp Epidemiol 1997;18:679-80.

51. Montecalvo MA, Shay DK, Gedris C, et al. A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant Enterococci: Colonized patients pose an infection control risk. Clin lnfect Dis 1997;25:929-30.

52. Mainous MR, Lipsett PA, O’Brien M, The Johns Hopkins SICU Study Group. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? Arch Surg 1997;132:76-81.

53. Stroud L, Edwards J, Danzig L, et al. Risk factors for mortality associated with enterococcal bloodstream infections. lnfect Control Hosp Epidemiol 1996;17:576-80.

54. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin lnfect Dis 1996;23:720-6.

55. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycinresistance. Infect Control Hosp Epidemiol 1995;16:105-13.

56. Boyce JM. Vancomycin-resistant Enterococcus. Detection, epidemiology, and control measures. lnfect Dis Clin North Am 1997;11:367-84.

57. Boyce JM, Mermel LA, Zervos MJ, et al. Controlling vancomycin-resistant Enterococci. lnfect Control Hosp Epidemiol 1995;16:634-7.

58. Lorian V, Fernandes F. Susceptibility of vancomycin-resistant Enterococci to environmental disinfectants. lnfect Control Hosp Epidemiol 1997;18:678-9.

59. Saurina G, Landman D, Quale JM. Activity of disinfectants against vancomycin-resistant Enterococcus faecium. lnfect Control Hosp Epidemiol 1997;18:345-7.

60. Anderson RL, Carr JH, Bond WW, Favero MS. Susceptibility of vancomycin-resistant Enterococci to environmental disinfectants. lnfect Control Hosp Epidemiol 1997;18:195-9.

61. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria: A report on the Rockefeller University workshop. N Engl J Med 1994;330:1247-51.

62. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 1993;269:598-602.

63. Belliveau PP, Rothman AL, Maday CE. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. Am J Health-Syst Pharm 1996;53:1570-5.

64. Anglim AM, Klym B, Byers KE. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycinresistant Enterococcus faecium. Arch lntern Med 1997;157: 1132-6.

65. Morgan AS, Brennan PJ, Fishman NO. lmpact of a vancomycin restriction policy on use and cost of vancomycinresistant Enterococcus. Ann Pharmacother 1997;31:970-3.

66. Burke CE, Piper J, Holloway W. Order form for restricting vancomycin prescribing. Am J Health-Syst Pharm 1997;54: 1893-7.

67. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant Enterococci. Clin Infect Dis 1996;23: 1020-5.

68. Quale J, Landman D, Atwood E, et al. Experience with a hospital-wide outbreak of vancomycin-resistant Enterococci. Am J Infect Control 1996;24:372-9.

69. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.

70. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [letter]. J Antimicrob Chemother 1997;40:135-6.

71. Davidson HE. New developments in Staphylococcus aureus resistance. Consul Pharm 1997;12:1218-9.

72. Ploy MC, Grelaud C, Martin C. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter; comment]. Lancet 1998;351:1212.

73. Boyce JM. Strategies for controlling methicillin-resistant Staphylococcus aureus in hospitals. J Chemother 1995;7(suppl 3):81-85.

74. Jernigan JA, Titus MG, Groschel DH, et al. Effectiveness of contact isolation during a hospital outbreak of methicillinresistant Staphylococcus aureus. Am J Epidemiol 1996;143: 496-504.

75. Edmond MB, Wenzel RP, Pasculle AW. Vancomycinresistant Staphylococcus aureus: Perspectives on measures needed for control. Ann Intern Med 1996;124:329-34.

76. Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: Treating S. aureus nasal carriage. Ann Pharmacother 1998;32(suppl):S7-S16.

77. McDonald LC, Kuehnert MJ, Tenover FC, et al. Vancomycinresistant Enterococci outside the healthcare setting: Prevalence, sources, and public health implications. Emerg Infect Dis 1997;3:311-5.

78. Shales D,Levy S, Archer G. Antimicrobial resistance: new directions. ASM News 1991; 57:455-8.

79. Gold HS, Moellering RC. Drug therapy: antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.

80. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP Working Group. JAMA 1996;275: 206-9.

81. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271:1831-5.

82. Appelbaum PC. Emerging resistance to antimicrobial agents in gram positive bacteria: pneumococci. Drugs 1996;51(suppl. 1):1-5.

83. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278: 901-4.

84. McIntyre P. Epidemiology and prevention of pneumococcal infections. Curr Opin Pediatr 1997;9:9-13.

85. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of b-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:36570.

86. Kristinsson KG. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 1997;3:117-23.

87. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273:214-9.

88. Bauchner H, Klein JO. Parental issues in selection of antimicrobial agents for infants and children. Clin Pediatr 1997; 36:201-5.

89. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7 A4, 3rd ed. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.

90. Jacobs MR, Bajaksouzian S, Palavecino-Fasola EL, et al. Determination of penicillin MICs by using a two or three disk diffusion procedure. J Clin Microb 1998; 36:179-83

91. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997;11: 867-74.

92. Butler JC, Jofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States, an update from the Centers for Disease Control and Prevention’s Pneumococcal Sentinel Surveillance System. J Infect Dis. 1996; 174:986 -93.

93. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1996; 15: 932-9.

94. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three, third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study. Diagn Microbiol Infect Dis 1996;25:89-95.

95. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-57.

96. Jacobs MR, Bajaksouzian S, Lin G, Appelbaum PC. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral agents. Abstracts of 98th General Meeting of the American Society for Microbiology, Atlanta, Georgia, May 1998. (Abstract A-31). American Society for Microbiology, Washington, DC.

97. Hoffman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.

98. Fenoll A, Bourgon C, Munoz R, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis. 1991; 13:56 – 60

99. Marton A, Gulyas M, Munoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolate of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163: 542-8.

100. Freidland IR, Klugman KP. Penicillin-resistant pneumococcal infections in South African children. Am J Dis Child 1992; 46:920-923.

101. Bonafede M, Rice LB. Emerging antibiotic resistance. J Lab Clin Med 1997;130:558-66.

102. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997;24(suppl. 1):S85-S88.

103. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377-82.

104. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumoniae in Barcelona, Spain. N Engl J Med 1995;333: 474-80.

105. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995;39:1988-92.

106. Radetsky MS, Istre GR, Johansen TL, et al. Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre. Lancet 1981; 282:771-3.

107. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339:405-8.

108. Reid R Jr, Bradley JS, Hihdler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J 1995;14:1104-5.

109. Lonks JR, Durkin MR, Meyerhoff AN, et al. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae. (Letter.) N Engl J Med 1995; 332: 893-4.

110. Chesney PJ, Davis Y, English BK, et al. Occurrence of Streptococcus pneumoniae meningitis during vancomycin and cefotaxime therapy of septicemia in a patient with sickle cell disease. Pediatr Infect Dis J 1995;4:1013-5.

111. Lister PID, Pong A, Chartrand SA, et al. Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother 1997;41:1926-32.

112. Paris MM, Ramilo 0, McCracken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995;39:2171-5.

113. Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Phys 1997;55:1647-54.

114. Pelton SI. Defining resistance: breakpoints and beyond implications for pediatric respiratory infection. Diagn Microbiol Infect Dis 1996;25:195-9.

115. Nelson CT, Mason EO Jr, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994;13:585-9.

116. Bartlett JG, Brieman RF, Mandell LA, File TM Jr. Community- acquired pneumonia in adults: guidelines for management. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-38.

117. Grimwood K, Collingon PJ, Currie BJ, et al. Position paper: antibiotic management of pneumococcal infections in an era of increased resistance. J Paediatric Child Health 1997; 33:287-95.

118. Goldstein FW. Choice of an oral b-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scand J Infect Dis 1997;29:255-7.

119. Aguilar L, Rosendo J, Balcabao P, Prieto J. Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin- susceptible and penicillin-resistant pneumococcal strains: a phase 1 study. Antimicrob Agents Chemother 1997;41: 1389-91.

120. Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance. J Chemother 1997;9(suppl 3):29-37.

121. Dowell SF, Butler JC, Giebink GS, et al. and the Drug Resistant Streptococcus pneumoniae Therapeutic Working Group. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.

122. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those of penicillin G, amoxicillin/clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime and cefdinir. Antimicrob Agents Chemother 1994;38:2902-4.

123. American Academy of Pediatrics. Special medical reports: AAP establishes treatment recommendations for invasive pneumococcal infections. Am Fam Phys 1997; 55:2859-60.

124. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-43.

125. Jacobs MR, Appelbaum PC. Antibiotic-resistant pneumococci. Rev Med Microbiol 1995;6:77-93.

126. Craig WA. Pharrnacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.

127. Goldstein FW, Garau J. 30 years of penicillin-resistant S. pneumoniae: Myth or reality? (Commentary) Lancet 1997; 350:233-4.

128. Spencer J, Gonzalez L III, Miller RP, Myers ML. Treatment of penicillin-resistant pneumococcus with penicillin: a case report. J Fam Pract 1997;44:499-503.

129. Poole MID. Otitis media complications and treatment failures: implications of pneumococcal resistance. Pediatr Infect Dis J 1995;14(suppl 4):S23-S26.

130. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.

131. Davies J. Bacteria on the rampage. Nature 1996;383:219-20.

132. Moellering RC Jr. Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 1998;26:1177-8.

133. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-9.

134. Moellering RC Jr. Past, present, and future antimicrobial agents. Am J Med 1995;99:11S-18S.

135. Weinstein MJ, Luedemann GM, Oden EM, Wagman GH. Everninomicin, a new antibiotic complex for Micromonospora carbonacea. Antimicrob Agents Chemother. Bethesda MD: American Society of Microbiology; 1965:24-32.

136. Linden PK, Paculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145-51.

137. Jones RN, Barrett MS, Erwin ME. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997;41:488-93.

138. Rosen H, Silver L, Hammond M. L-786,392: a releasable pharmacophore carbapenem active on MRS, VISA and VRE [Abstract]. Abstracts of the Infectious Disease Society of America. 36th Annual Meeting Denver, CO, 1998.

139. Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, et al. Oxazolidinones: new antibacterial agents. Trends Microbiol 1997;5:196-200.

140. Moellering RC Jr. Antibiotic resistance: lesson for the future. Clin Infect Dis 1998;27(Suppl. 1):S135-40.

141. Alborn WE Jr., Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2282-7.

142. Brickner SJ. Oxazolidinone antibacterial agents. Current Pharmaceutical Design 1996;2:175-94.

143. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996;39:680-5.

144. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid of translation reactions. Antimicrob Agents Chemother 1997;41:2132-6.

145. Murray RW, Schaadt RD, Zurenko GE, Marotti KR. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription assay. Antimicrob Agents Chemother 1998;42:947-50.

146. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U- 100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.

147. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance in pharmacokinetics after intravenous dosing twice daily for 7.5 days [Abstract]. In: proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October 1997, Toronto, Canada.

148. Batts DH. Linezolid clinical development program: end of Phase II results [Abstract]. Abstracts of 2nd European Congress of Chemotherapy. Hamburg, Germany, 10-13 May 1998.